Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Patients with solid tumors or lymphoproliferative disease

- Patients receiving chemotherapy

- Patients for whom erythropoietin is indicated for pre-study hemoglobin level and
observed anemic symptoms: Hgb < 11 dL (6.83 mmol/L)

Exclusion Criteria:

- Resistant hypertension

- Acute chronic bleeding within 3 months

- Iron deficiency, unmanageable prior to study

- Hypersensitivity to the active substance or any of the excipients of the product

- Pregnant or breast-feeding women

- Epoetin treatment within 6 months prior to study